Interphase fluorescence in situ hybridization analysis of CD19-selected cells: Utility in detecting disease in post-therapy samples of B-cell neoplasms.

CONTEXT The detection of low-level persistent or relapsed B-cell neoplasms, particularly post-therapy, can be challenging, often requiring multiple testing modalities. OBJECTIVE Here we investigate the utility of CD19-based selection of neoplastic B-cells (CD19S) as an enrichment strategy to improve the detection rate of cytogenetic abnormalities in post-therapy samples of B-cell neoplasms, especially those with low-level disease. DESIGN In a cohort largely comprised of post-therapy B-ALL and CLL samples, we performed fluorescence in situ hybridization (FISH) analysis on CD19-selected cells (CD19S FISH) in 128 specimens from 88 patients, and on non-selected cells (NS FISH) in a subset of cases. The FISH findings were compared with the concurrent flow cytometry (FC) results in all samples and molecular analysis in a subset. RESULTS CD19S FISH was able to detect cytogenetic aberrations in 86.0% of post-therapy samples with evidence of disease as determined by routine or MRD FC, compared to 59.1% of samples by NS FISH. CD19S FISH detected significantly higher percentages of positive cells compared to NS FISH (p < 0.001). Importantly, CD19S FISH enabled the detection of emergent subclones (clonal evolution) associated with poor prognosis. CONCLUSIONS CD19S FISH can be useful in daily diagnostic practice. Compared to NS FISH, CD19S FISH is quantitatively and qualitatively superior for the detection of cytogenetic aberrations in B-cell neoplasms, which are important for risk stratification and optimal management of patients with B-cell neoplasms, especially in the relapsed setting. Although CD19S FISH has a diagnostic sensitivity inferior to that of MRD FC, the sensitivity of this modality is comparable to routine FC for the evaluation of low-level disease in the post-therapy setting. Moreover, CD19S samples are invaluable for additional molecular and genetic analyses.

[1]  A. Órfão,et al.  Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Bhagat,et al.  Detection of Nonhematologic Neoplasms by Routine Flow Cytometry Analysis. , 2019, American journal of clinical pathology.

[3]  W. Erber,et al.  “Immuno‐flowFISH” for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[4]  Martin J. Aryee,et al.  Epigenetic evolution and lineage histories of chronic lymphocytic leukemia , 2019, Nature.

[5]  M. Syed,et al.  Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. , 2019, The Journal of molecular diagnostics : JMD.

[6]  Feng Li,et al.  Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis , 2019, Annals of Hematology.

[7]  S. Chocholska,et al.  Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease , 2018, Oncotarget.

[8]  M. Loh,et al.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. , 2018, Blood.

[9]  D. Neuberg,et al.  The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy , 2017, Nature Communications.

[10]  G. Salles,et al.  Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas , 2017, Expert review of molecular diagnostics.

[11]  Quentin Lecrevisse,et al.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. , 2017, Blood.

[12]  M. Jarošová,et al.  Chromosomal aberrations in childhood acute lymphoblastic leukemia: 15-year single center experience. , 2016, Cancer genetics.

[13]  Gabriel P López,et al.  Microfluidic cell sorting: a review of the advances in the separation of cells from debulking to rare cell isolation. , 2015, Lab on a chip.

[14]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[15]  W. Rigby,et al.  Rituximab mediates loss of CD19 on B cells in the absence of cell death. , 2012, Arthritis and rheumatism.

[16]  Shuqiang Li,et al.  MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells , 2011, PloS one.

[17]  Jeffrey A Jones,et al.  Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation , 2010, British journal of haematology.

[18]  J. Garcia-conde,et al.  Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia , 2009, Haematologica.

[19]  Y. Zhang,et al.  Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. , 2007, Experimental oncology.

[20]  Irene Ghobrial,et al.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. , 2006, Blood.

[21]  D. Campana,et al.  Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.

[22]  A Thiel,et al.  Immunomagnetic cell sorting--pushing the limits. , 1998, Immunotechnology : an international journal of immunological engineering.

[23]  M. Hallek,et al.  Prognostic factors in chronic lymphocytic leukemia—what do we need to know? , 2011, Nature Reviews Clinical Oncology.

[24]  T. Klingebiel,et al.  Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis , 2010, Bone Marrow Transplantation.